Viking Therapeutics – 2026-01-14 - increase Confidence 8/10

VKTX – increase in Days/Weeks

Viking Therapeutics reported negative free cash flow of $87.79M (TTM), yet holds $714.57M in cash, providing a strong runway. Completion of patient enrollment in the Phase 1 maintenance dosing study for VK2735 in obesity (Jan 8, 2026) and full enrollment in the Phase 3 VANQUISH-1 trial signal near-term data readouts.

Why This Matters

The biotech sector is highly sensitive to clinical development inflection points, and Viking’s recent enrollment completions—especially in the pivotal Phase 3 obesity trial—position the company for imminent catalysts. With substantial cash reserves covering years of operations despite negative FCF, the risk of dilution is low, allowing the market to focus purely on upcoming efficacy data, which could re-rate the stock toward the $93.39 analyst target.

Key Insights

• Cash Position: $714.57M in cash vs. $87.79M annual cash burn → ~8+ years of runway
• News Impact: Phase 3 enrollment complete for VK2735 in obesity → near-term data readout expected, driving speculative upside
• Risk/Offset: No revenue or profitability yet; stock trades on pipeline progress, increasing volatility risk if data disappoints

Practical Implications

• Bull Case: Positive VK2735 maintenance dosing data or early Phase 3 signals → 20–30% rally toward $43 52-week high
• Bear Case: Delayed data or safety concerns in trials → pullback to $25 support, though cash cushion limits downside
• Confidence: 8/10 – High-impact catalysts imminent, strong cash position, and analyst target implies significant upside

Prediction: increase

Reference:

• https://finance.yahoo.com/news/viking-therapeutics-announces-completion-enrollment-120000961.html
• https://finance.yahoo.com/quote/VKTX/